The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for…
Chimeric antigen receptor (CAR) T-cells have been a key focus in cancer research over recent years; however, T-cells are not…
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hôpital Avicenne,…
Measurable residual disease (MRD) is rising in popularity as a prognostic indicator in a variety of blood cancer types. We…
Esther Oliva, MD, of the Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, presented preliminary results from her Phase…
The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia…
Daunorubicin is commonly used to treat acute myeloid leukemia (AML). In this video, Christoph Röllig, MD, of the University Hospital…
Measurable residual disease (MRD) can be detected using two main techniques: next-generation sequencing and flow cytometry. Here, Bruno Paiva, PhD,…
Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute…
Al Benson III, MD, FACP, explains how tumor-sidedness impacts colorectal cancer treatment algorithms.
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Bobby Green, MD, explains Flatiron’s clinico-genomic database helping shed light on the cost-effectiveness of next-generation sequencing.
Roy S. Herbst, MD, PhD, shares his thoughts on whether Keynote 189 impacted view of PDL-1 expression and patient selection.
Celestia S. Higano, MD, shares the outcomes from the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer are impacting…
Edgardo S. Santos, MD, FACP, shares his opinion on continued pemetrexed maintenance.
Joan Schiller, MD, shares her opinion on continuing pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients…
Al Benson III, MD, FACP, explains the role of I-O and immunotherapy when treating colorectal cancer.
Bobby Green, MD, explains Flatirons clinico-genomic database and how it may be used to direct treatments.
Joan Schiller, MD, shares Keynote 189 and whether the data impacts her view of PDL-1 expression and patient selection at…
Roy S. Herbst, MD, PhD, talks about Exciting developments from the 2018 Annual Meeting.
Bobby Green, MD, shares what people will most likely be talking about from the 2018 Annual Meeting.
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his…
Celestia S. Higano, MD, shares how MRIs improved the diagnosis for prostate cancers.
Robert A. Figlin, MD, talks about how checkpoint inhibitors factor into 1st line RCC patient treatments.
Al Benson III, MD, FACP, Professor of Medicine, Northwestern University, shares the outcomes of the ECOG-ACRIN study in advanced pancreatic…
Edgardo S. Santos, MD, FACP, shares exciting developments coming out of the 2018 Annual Meeting
Celestia S. Higano, MD, talks about imaging as a cost-effective solution for diagnosis of prostate cancer.
Robert A. Figlin, MD, talks about Deciding which metastatic RCC patients should get a TKI as 1st line therapy.
Dr. Benson, Professor of Medicine, Northwestern University, shares which molecular markers are most important when treating colorectal cancer patients.
Multiple myeloma (MM) is known to have a dysregulatory effect on the immune system; however, preclinical trials have shown that…
Allogeneic stem cell transplantation (allo-SCT) is the only curative option for many patients with hematological malignancies. It is therefore crucial…
Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk…
Dr. John Kisiel, MD, Mayo Clinic, talks Sensitivity for BCLC for Stage A was 93%| Detect Hepatocellular Carcinoma Lesions in…
Dr. John Kisiel, MD, Mayo Clinic, talks about Fairly Consistent Distribution of Liver Diseases | No Association with Specific Diseases…
Dr. John Kisiel, MD, Mayo Clinic, talks about Develop Novel, Non-Invasive Biomarkers | Clinical Validation Study in Hepatocellular Carcinoma for…
A picture can say a thousand words and, in this case, it is all too true; understanding tumour metabolism, bone…
Although the rates of progression-free survival are steadily increasing, the majority of multiple myeloma (MM) patients still face relapse. Here,…
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
The androgen synthesis inhibitor abiraterone increases the survival of men with metastatic prostate cancer; however, existing clinical trials consistently over-represent…
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses clinical trials that are currently investigating the…
After promising results form the CHAMPION 1 study (NCT01677858), which increased median progression-free survival to >1 year for relapsed/refractory multiple…
Acute lymphoblastic leukemia (ALL) treatment regimens are long and debilitating, which is especially hard on young adults who are already…
With the remarkable success of the US Bone Marrow Transplant Clinical Trials Network (BMT CNT), founded by Mary Horowitz, in…
Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important…
In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, discusses the importantance of involving…
The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies…
Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Paul Richardson, MD,…
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid…
Autologous stem cell transplantation can prove to be safer in some instances compared with allogeneic transplantation for treating hematological malignancies,…
Speaking from the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Bart Biemond, MD, PhD, from…
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory…
While the treatment landscape of chronic lymphocytic lymphoma (CLL) has been exciting with many breakthrough therapies, there are still key…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
In this interview, Bart Biemond, MD, PhD, from the Academic Medical Centre, Amsterdam, Netherlands, provides an insight is provided into…
It is important that current techniques for the monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) are…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Minimal residual disease (MRD) is the small number of leukemic cells that remain after treatment and there are no signs…
Willem Ouwehand, MD, PhD, of the University of Cambridge, Cambridge, UK updates us on developments in clinical hematology at the…
The Checkmate 205 study (NCT02181738) is looking at nivolumab in previously treated and newly diagnosed patients with classical Hodgkin lymphoma.…
Difficult multidisciplinary team decisions occur within follicular lymphoma (FL) due to the heterogeneity that exists within the disease. In this…
Acquired von Willebrand disease is a rare condition that has been reported in post-autologous bone marrow transplant (BMT) patients, though…
There have been many promising therapies for lymphoma recently, with several interesting clinical trials in progress or upcoming. In this…
Willem Ouwehand, MD, PhD, of the University of Cambridge, Cambridge, UK, discusses non-malignant hematology, particularly rare inherited disorders of hematopoietic…
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, of Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, gives an overview of…
HaemSTAR is a network of clinical hematology registrars within the UK that aims to promote clinical research in non-malignant hematology.…
While there has been a range of new therapeutic options emerging for lymphoma, this introduces the challenge of assessing them…
A large proportion of gynecological tumors are classed as rare tumors because of their variable morphologies and pathologies. We interviewed…
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a follow-up clinical scenario to elucidate the latest…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a clinical scenario to elucidate the latest advances…
Aplastic anemia (AA) results in T-cells attacking bone marrow stem cells, causing loss of all blood cell types. Generally, this…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-apoptotic BCL2…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-CD20 agents.…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of BRC signaling…
Collaboration for Oncology Data in Europe (CODE) is an alliance that brings together patient associations, charities and treatment centers in…
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as…
Stephen Robinson, MBBS, MRCP, MRCPath, PhD, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, describes his role in a…
Gaucher disease (GD) is a rare genetic disorder which is seldom diagnosed because of its rarity, although diagnoses can be…
Stephen Robinson, MBBS, MRCP, MRCPath, PhD, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, speaks to us about one…
Diversity in blood donors is crucial; there is a deficit in ethnic minority donors, which has a severe impact on…
Autologous transplant is unsuccessful in ~50% of Hodgkin lymphoma (HL) patients. Here, Stephen Robinson, MBBS, MRCP, MRCPath, PhD, of University…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nina Shah, MD, from the University…
Marianne Nicolson, MD, FRCP, BSc, MBChB, of NHS Grampian, Aberdeen, UK, gives an overview of a session discussing lung cancer…
The integration of scientific research into clinical practice is one of the many challenges healthcare professionals face. Here, Mariam Jamal-Hanj,…
Vicky Coyle, MD, of Queen’s University Belfast, Belfast, UK, spoke to us at the UK Oncology Forum (OF) 2018, held…
Mariam Jamal-Hanj, BSc, MBBS, PhD, of University College London, London, UK, discusses her talk regarding intra-tumor heterogeneity within lung cancer…
Aspirin has been suggested as a preventative measure for several cancer types, in particular colorectal cancer, as Vicky Coyle, MD,…
Kai-Keen Shiu, MRCP, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, speaks to us about future directions…
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Guillermo Garcia-Manero, MD, of the…
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in…
Currently there is a good variety of treatments available for patients with relapsed multiple myeloma (MM). Here, Rakesh Popat, BSc,…
Data from the ENDEAVOUR trial (NCT01568866) has shown that using carfilzomib plus dexamethasone (Kd) is more effective in treating relapsed/refractory…
In this interview, recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Rakesh Popat, BSc,…
Tumor suppressor gene TP53 is associated with aggressive disease activity when inactivated in a variety of tumor types, including multiple…
Treatment of multiple myeloma (MM) has improved greatly over the past few years; however, certain patients remain at high risk…
Voluntary, non-remunerated blood donations are uncommon in developing countries and ethnic minority populations. Kenneth Charles, MBBS, FRCP, FRCPath(Haem), from the…
Tumor suppressor gene TP53 is associated with aggressive disease activity when inactivated in a variety of tumor types, including multiple…
This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted…
One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD)…
There are multiple methodologies for the testing of measurable residual disease (MRD), which each come with various pros and cons,…
One of the major challenges of measurable residual disease (MRD) utilization is the standardization of its measurement and reporting. Here,…
In this interview with Andrew Armstrong, MD, of Duke University, Durham, NC, speaking from the 2018 American Society of Oncology…
Osteomimicry has been studied for the last few decades, and is the process by which cancer cells can spread to…
Lung cancer is the leading cause of cancer mortality in the United States, and low-dose CT scans are advised as…
Speaking from the British Society for Hematology (BSH) 2018 Annual Scientific Meeting in Liverpool, UK, Derralyn Hughes, MA, DPhil, FRCP,…
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva)…
The TroMBone trial (ISRCTN15704862), comparing radical prostatectomy with systemic therapy vs. systemic therapy alone in men with oligometastatic prostate cancer,…
Robert Kreitman, MD, from the National Cancer Institute, Bethesda, MD, discusses a clinical trial using the recombinant immunotoxin, moxetumomab pasudotox,…
Joseph M. Connors, MD shares Increase in Toxicity of Two Different Types for ECHELON-1 Trial at AACR 2018
Joseph M. Connors, MD shares No Difference in Overall Survival at AACR 2018
Joseph M. Connors, MD shares FDA Reviewing Details of the Study | Approved Brentuximab at AACR 2018
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR…
At the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Steve Williamson, from Northumbria NHS Foundation Trust, Newcastle upon…
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in…
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL),…
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use…
In this interview, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, details the importance…
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held…
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas…
MATRix immunochemotherapy induction therapy has produced promising results in the recent IELSG32 trial (NCT01011920) for primary CNS lymphoma (PCNSL). However,…
Although there have been significant advancements in the treatment of acute lymphoblastic leukemia (ALL) in the last few decade, many…
Sickle cell disease (SCD) is a group of inherited blood disorders that result in a variety of acute illnesses, ultimately…
The multitude of novel therapies in the field of chronic lymphocytic leukemia (CLL) paves the way for exciting future possibilities.…
Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of…
Guy Pratt, MD, FRCP, FRCPath, of University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses recent guideline changes within multiple…
Challenges are often encountered when implementing guidelines into clinical practice. Here, Guy Pratt, MD, FRCP, FRCPath, of the University Hospitals…
The multitude of novel therapies present within the field of lymphoma has inevitably given rise to an assortment of challenges.…
Up-and-coming mutation analyses are facilitating the precision treatment of lymphoma. Here, Jude Fitzgibbon, BA, PhD, of the Barts Cancer Institute,…
The next 4 years are going to be exciting and productive for transplant research across a broad range of hematological…
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of…
Venous thromboembolism (VTE) effects 20% of all cancer patients. In this interview with Cihan Ay, MD, from the Medical University…
Physicians may encounter difficulties integrating proton beam therapy amongst existing radiotherapy options. Here, Neil Burnet, MA, MBBChir, FRCR, MD, of…
The introduction of proton beam therapy has brought with it a multitude of implications, which Neil Burnet, MA, MBBChir, FRCR,…
As Chair of the meeting, Ruth Plummer, MD, of Newcastle University, Newcastle, UK, give us her overview of the highlights…
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the…
Joseph M. Connors, MD shares FDA Reviewing Details of the Study | Approved Brentuximab at AACR 2018
Joseph M. Connors, MD shares Trial Established Use of Brentuximab + AVD As Viable Option for Clinicians at AACR 2018
Joseph M. Connors, MD shares Specific Endpoint for the Comparison of the Two Treatments for ECHELON-1 Trial at AACR 2018
Joseph M. Connors, MD shares Results from ECHELON-1 Trial at AACR 2018
Monoclonal antibody therapy has been around for a long while, but recent technological advancements have allowed for more tailored and…
A Phase I trial (NCT02074839) investigating the IDH1 inhibitor ivosidenib has demonstrated encouraging results in relapsed/refractory acute myeloid leukemia (AML).…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Anthony Mato, MD, MSCE, from…
Intolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic…
With the impressive results from initial trials using CAR T-cells, excitement surrounding this modality as a curative therapy was high.…
In this interview, Faith Davies, MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, discusses the various drugs…
In this interview, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, provides an overview of…
Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher…
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Anita Hill, MBChB (Hons), MRCP,…
Thrombosis is the leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH). In this interview, Anita Hill, MBChB…
Francis J. McGovern, MD explains the need to Educate to Patients to Only Take What is Needed | Pain Level…
Francis J. McGovern, MD explains Blocking Inflammatory Pain Pathway | Anesthetic Depends on Expertise of Anesthesiologist at AACR 2018
Francis J. McGovern, MD explains the Perioperative Opioid-Sparing Analgesia Strategies for Enhanced Recovery after Urologic Surgery at AACR 2018
In this interview, Jeff Evans, PhD, from the University of Glasgow, Glasgow, UK, provides an update on the current landscape…
Gerhardt Attard, MD, PhD, FRCP, of the The Royal Marsden NHS Foundation Trust, London, UK, speaks from the UK Oncology…
Microsatellite instability (MSI) in tumors is a known predictor of response to certain therapies in gynecological cancer. In this video,…
Aman Chauhan, MBBS, University of Kentucky shares Launching Phase 2 Trial In Multi-Center Fashion | Currently Evaluated in Bone Marrow…
Brian I. Rini, MD, Cleveland Clinic explains Anti-VEGF Therapy Has Been Standard | Field is Changing Dramatically at Annual Meeting…
Aman Chauhan, MBBS, University of Kentucky shares Telotristat for Carcinoid Syndrome Diarrhea | Wish for More Trials, Products, Pipeline Drugs…
Brian I. Rini, MD, Cleveland Clinic explains Adding Amino Modulators to Increase Efficacy | Starting to Get Complete Response Rates…
Aman Chauhan, MBBS, University of Kentucky shares Data Showed Diarrhea From Chemotherapy at Annual Meeting 2018
Brian I. Rini, MD, Cleveland Clinic explains Combinations Being Developed for Kidney Cancer | Efficacy Will Drive Treatment Choices at…
Aman Chauhan, MBBS, University of Kentucky explains enterade® is a Medical Food | Does Not Need Formal Prescription. OTC at…
Brian I. Rini, MD, Cleveland Clinic shares Patient Reported Outcomes Measure Tolerabilty | Trial Showed Benefits for Regimen Over Sunitinib…
Aman Chauhan, MBBS, University of Kentucky explains enterade® Amino Acid Based Rehydration Solution | 70% of Patients Had Benefit in…
Brian I. Rini, MD, Cleveland Clinic explains PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals at Annual Meeting…
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Target Tumors More Effectively | Better Combinations, Find…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Focus on Potentially Predictive Markers | Neutrophil-to-Lymphocyte Ratio Blood Test May…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Annual Meeting Helps Impact Ability to Communicate |…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains CaM6 In Collaboration w German Cancer Ctr. | ILDR2 In Collaboration w Compugen…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Moving Toward Precision Medicine | Field is Growing…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Thorium Platform Based on Initial Radium (Xofigo) | Thorium Delivers Alpha Radiation at…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Bladder Cancer is No Longer Just One Disease…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Erdafitinib Currently Not FDA-Approved | Granted Breakthrough Designation…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains DHODH Inhibitor Pyrimidine Synthesis | FGFR Inhibitor has Response Rate of 24% at…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Studies for Fibroblast Growth Factors Receptors | Mutations…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at Annual…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Therapy for Metastatic Urothelial Carcinoma | Erdafitnib, a…
Immunotherapy treatment within oncology is a field showing great promise. Here, Alexandra Leary, MD, PhD, of the Gustave Roussy Institute…
Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity…
The Systemic Anti-Cancer Therapy (SACT) Competency Passport, produced by leading cancer nuses in partnership with the UK Oncology Nursing Society…
Sonja Hoy, BS, PGDip, of The Royal Marsden NHS Foundation Trust, London, UK, discusses the importance of good oral hygiene…
How to maintain optimal patient safety and wellbeing is a constant concern and priority for healthcare professionals. At the UK…
Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug…
CT scans are currently the standard for mapping targeted areas for cancer treatment; however, MRI has been shown to produce…
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and…
The Genomics England program could play a key role in personalizing the treatment of patients with follicular lymphoma, through helping…
The field of cardio-oncology is growing on both a national and international scale. In this interview, Alex Lyon, MA, BM…
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac…
With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced…
Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone marrow,…
An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize…
The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung…
The management of patients with metastatic non-small cell lung cancer (NSCLC) is a field which has seen drastic improvement in…
Pierluigi Porcu, MD, Thomas Jefferson University, shares Find Better Predictive Biomarkers for Response | Expand Data to Other of T-Cell…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for…
Pierluigi Porcu, MD, Thomas Jefferson University talks about a Huge Need for Better Therapy for CTCL | Hope for FDA-Approval…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab…
Pierluigi Porcu, MD, Thomas Jefferson University explains Compliance of MAVERICK Dataset was 95%-96%| Analysis Based on Longitudinal Assessment at Annual…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, Poor-Risk Patients Enrolled in Study for Surgery | Surgery is Not Significantly…
Pierluigi Porcu, MD, Thomas Jefferson University explains Efficacy Moga, Room for Improvement | In Terms of Response Rate & Progression-free…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Lacking Data In Current Kidney Cancer Landscape | May Extrapolate Previous…
Pierluigi Porcu, MD, Thomas Jefferson University explains Quality-of-Life Data for MAVERICK Study | Using 2 Specific Tools for CTCL Had…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery &…
Saby George, MD, FACP, Roswell Park Cancer Institute, talks about CARMENA Study Showed Sunitnib Alone | Studies Showing Single-Agent Checkpoint…
Ray Comenzo, MD, Tufts Medical Center, explains If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open…
Ajai Chari, MD, Mt. Sinai, explains Isatuximab, Carfilzomib & Dexamethasone | Phase 1 Study Combining Drugs at Annual Meeting 2018
Saby George, MD, FACP, Roswell Park Cancer Institute, shares CARMENA Study Results | Sunitinib Not Inferior to Sunitinib Following Nephrectomy…
Ray Comenzo, MD, Tufts Medical Center, explains Daratumumab in Subcutaneous Form is Safe | Can Benefit Relapsed Light-Chain Amyloid at…
Ajai Chari, MD, Mt. Sinai, talks about Getting Regimens Approved | Avoid Insurance & Regulatory Barriers at Annual Meeting 2018
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Checkmate-214 has a Higher Response Rate | 9% of Patients Went…
Ray Comenzo, MD, Tufts Medical Center, explains Earlier Diagnosis for SMM or MGUS | At Risk of Progressing to Light-chain…
Ajai Chari, MD, Mt. Sinai, explains Daratumumab’s Main Limitation | Length of Infusion in Infusion-related Reactions at Annual Meeting 2018
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination…
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a…
Ray Comenzo, MD, Tufts Medical Center, shares Preparation & Administration Processes Are Safe | Response Rate Will Improve at Annual…
Ajai Chari, MD, Mt. Sinai , explains, Unmet Need for LenD Refractory Patients | No One Regimen that is Appropriate…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares Checkmate-214 Not for All Kidney Cancer Patients | Study for Advanced…
Ray Comenzo, MD, Tufts Medical Center explains, ANDROMEDA Phase 3 Trial | Randomized Trial for Systemic Light-Chain Amyloid at Annual…
Ajai Chari, MD, Mt. Sinai discusses Data from MMY1001 Study | Update from Lenalidomide Refractory Subgroup at Annual Meeting 2018
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation…
Ana Limon Carrera, Takeda Oncology, Mechanism of Action Molecule – Pevonedistat | Based on Protein Homeostasis Developed by Takeda at…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains First In-Class Agent Targeting PD-L1 & TGF-? | There Are…
Ana Limon Carrera, Takeda Oncology, talks about Working in Leukemias, Will Enter into Solid Tumors | Molecule TAK-931 is the…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Combining TGF-? & PD-L1 is Developing One Drug | Very…
Ana Limon Carrera, Takeda Oncology, talks about Studying Tumors in Pancreatic & Colorectal Patients | Hope to Confirm Safety &…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Look at Single-Agent Activity in Larger Studies | Vaccines Combining…
Ana Limon Carrera, Takeda Oncology, Additional Cell-Cycle Modulators is of Great Interest | Molecule w/ Safety Profile Combines Well with…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Analysis of HPV-Positive Malignancies | TGF-? Dysregulation is Seen in…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Submitting Update of Monotherapy to ESMO | Closure of ATLANTIS Trial…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Far Along Development in SCLC | American Oncologists Less Familiar w…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Development in Small Cell has been Much Slower | Most Drivers…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Lurbinectedin More Pronounced in Overall Survival | OS Endpoint is Preferable…
Pascal Besman, Chief Operating Officer of PharmaMar, shares Investigator Sponsored Trials in Europe & US | With Immuno-Oncology Checkpoint Inhibitors…
Pascal Besman, Chief Operating Officer of PharmaMar, shares a Randomized Trial of Topotecan & CAV | Monotherapy Will Have Up…
Pascal Besman, Chief Operating Officer of PharmaMar, shares an Update on Relapsed SCLC Monotherapy Trial | Overall Survival Data of…
Ana Limon Carrera, Takeda Oncology, shares TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains M7824 – Novel Bifunctional Protein | Anti-Body Targeting PD-L1, Sequester…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco explains Talazoparib is Effective in Neoadjuvant Setting | Combine…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US |…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1…
Despite recent advancements in CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), standard chemotherapy is still the…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses the early trials that are currently underway to…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains MSK Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic…
Paul Nghiem, MD, PhD, University of Washington, shares MCC Needs to be Managed in Multidisciplinary Way | Oncology, Surgery, Radiation…